title: In vitro effect of IL-17D on human ovarian carcinoma cells and inherent immunity.
abstract: This study explored the expression of interleukin 17D (IL-17D) secreted by human ovariancarcinoma cells and the effect of exogenous IL-17D transfection on MICA, which is the ligand of NKG2D, on the surface of ovary carcinoma cells. Human ovarian papillary serous adenocarcinoma cell line SKOV3, empty vector control cell line SKOV3/vector, exogenous human IL-17D stable-transfected cell line SKOV3/IL-17D, as well as cisplatin (CDDP)-resistant cell SKOV/CDDP were cultured; ovarian adenocarcinoma cell line OVCAR-3, empty vector control cell line OVCAR3/vector and OVCAE3/IL- 17D were observed under a microscope. In the study, methyl-thiazolyl-tetrazolium (MTT) method was used to detect the inhibition rate, resistance index and proliferation of SKOV3 and SKOV3/CDDP. It was found that the expression of IL-17 D in SKOV3/CDDP was much higher than that of its parent cell line SKOV3; IL-17D might be correlated to the drug resistance of cells; the proliferation of SKOV3 transfected with IL-17D was significantly accelerated, indicating IL-17D may be effective in promoting the growth of oncocyte.
authors.affiliation: Department of Obstetrics and Gynecology, First Affiliated Hospital of Hena University of Science and Technology, Luoyang, Henan, China.
authors.forename: L L
authors.initials: LL
authors.lastname: Fan
authors.affiliation: Department of Obstetrics and Gynecology, First Affiliated Hospital of Hena University of Science and Technology, Luoyang, Henan, China.
authors.forename: X Z
authors.initials: XZ
authors.lastname: Xue
authors.affiliation: Department of Obstetrics and Gynecology, First Affiliated Hospital of Hena University of Science and Technology, Luoyang, Henan, China.
authors.forename: N
authors.initials: N
authors.lastname: Jiao
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000231:Adenocarcinoma, Papillary / Q000473:pathology; D002455:Cell Division; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D018284:Cystadenocarcinoma, Serous / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D020381:Interleukin-17 / Q000235:genetics / Q000502:physiology*; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D010051:Ovarian Neoplasms / Q000473:pathology*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D014162:Transfection
chemical_list: D015395:Histocompatibility Antigens Class I; C464462:IL17D protein, human; D020381:Interleukin-17; C099187:MHC class I-related chain A; D009363:Neoplasm Proteins; D011993:Recombinant Fusion Proteins; D002945:Cisplatin